Retatrutide: Eli Lilly's Triple Agonist Full Review

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Retatrutide is a triple agonist from Eli Lilly. It demonstrated significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes Lilly's Retatrutide Phase 3 Diabetes Trial.
This investigational drug is currently being studied in participants who have obesity or are overweight Retatrutide Obesity/Overweight Study Details.
Eli Lilly is also developing orforglipron, an oral GLP-1 that helped people maintain weight loss after switching from injectable incretins.
Orforglipron delivered weight loss of up to an average of 27.3 lbs in one pivotal Phase 3 trial in adults with obesity Lilly's Orforglipron Weight Loss Results.

Eli Lilly's retatrutide is an exciting new investigational drug showing strong promise in treating type 2 diabetes and obesity. Our complete retatrutide evidence review pulls together every trial and dose in one place. This triple agonist has already demonstrated significant reductions in A1C levels and body weight during its initial Phase 3 trials for type 2 diabetes, marking it as a potentially powerful new option for patients Lilly's Retatrutide Phase 3 Diabetes Trial. Beyond diabetes, the drug is also actively being evaluated for its effects on weight management in individuals who are overweight or have obesity, with specific studies like NCT05929066 currently recruiting participants to gather more comprehensive data on its efficacy and safety in this population Retatrutide Obesity/Overweight Study Details. The development of retatrutide builds on Eli Lilly's broader portfolio of metabolic medications, which includes other innovative treatments such as orforglipron, an oral GLP-1 medication that has shown promising results in weight loss, with an average reduction of 27.3 lbs in one Phase 3 trial Lilly's Orforglipron Weight Loss Results. These advancements highlight a significant effort to address the complex challenges of metabolic health.

What is Retatrutide?

Retatrutide, known scientifically as LY3437943, is an investigational drug developed by Eli Lilly and Company. It stands out in the growing field of metabolic medications because it is a triple agonist. This means it works by activating three different hormone receptors in the body. These receptors are for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Current GLP-1 medications, like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza), typically target one or two of these receptors. By engaging all three, retatrutide aims to provide a more comprehensive approach to managing blood sugar and body weight. The drug is still in clinical trials, meaning it has not yet been approved by regulatory bodies for commercial use. Its development is part of Lilly's ongoing research into innovative treatments for complex conditions such as type 2 diabetes and obesity. The triple-agonist mechanism is designed to leverage the natural pathways that regulate metabolism, appetite, and energy balance.

The concept of a triple agonist represents an evolution in pharmaceutical science for metabolic disorders. GLP-1 agonists, for example, are well-known for stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. GIP agonists also enhance insulin secretion and may have additional effects on fat metabolism. Glucagon, traditionally associated with raising blood sugar, also plays a role in energy expenditure and satiety when modulated in specific ways. By combining the actions of these three hormones, retatrutide is hypothesized to offer enhanced benefits over single or dual agonists. Researchers believe this multi-faceted approach could lead to more significant improvements in glycemic control and weight loss. Eli Lilly is carefully studying the precise impact of this triple action in its clinical trial programs. These studies evaluate how the drug affects various physiological processes in human participants. The goal is to understand the full scope of its therapeutic potential and to ensure its safety and effectiveness before it can be considered for wider medical use. The investigational nature of retatrutide means that all findings are preliminary until the full clinical trial process is complete and reviewed by health authorities.

The journey of an investigational drug like retatrutide involves rigorous testing across multiple phases of clinical trials. These phases systematically assess the drug's safety, dosage, and efficacy in human subjects. Phase 1 trials typically involve a small group of healthy volunteers to determine initial safety and pharmacokinetics. Phase 2 trials expand to a larger group of patients with the target condition to evaluate effectiveness and side effects. Phase 3 trials, which retatrutide has entered for type 2 diabetes and is also undergoing for obesity/overweight, involve hundreds or thousands of patients to confirm efficacy, monitor adverse reactions, and compare it to existing treatments or placebo. The positive results observed in its first Phase 3 trial for type 2 diabetes are a significant milestone for retatrutide. These findings suggest that the triple-agonist mechanism is indeed capable of producing meaningful clinical outcomes, such as significant reductions in A1C and weight. The continued studies, including those focused specifically on obesity, will provide further insights into its broader applicability and long-term benefits. Understanding what retatrutide is—an investigational triple agonist—is key to appreciating its potential role in future metabolic disease management.

How Does Retatrutide Work for Type 2 Diabetes?

Retatrutide works for type 2 diabetes by targeting three key hormone receptors: GLP-1, GIP, and glucagon receptors. This triple-agonist action helps to improve blood sugar control and reduce body weight, which are both critical for managing type 2 diabetes. In its first Phase 3 trial for the treatment of type 2 diabetes, retatrutide demonstrated significant reductions in A1C levels and also led to significant weight reductions Lilly's Retatrutide Phase 3 Diabetes Trial. This multi-target approach is designed to address various aspects of glucose metabolism and energy balance that are often disrupted in individuals with type 2 diabetes.

The GLP-1 receptor activation by retatrutide plays a crucial role in glucose regulation. When activated, GLP-1 receptors stimulate the pancreas to release insulin in a glucose-dependent manner. This means insulin is released only when blood sugar levels are high, reducing the risk of hypoglycemia. GLP-1 also suppresses the release of glucagon, a hormone that raises blood sugar, and slows down gastric emptying, which helps to prevent sharp spikes in blood sugar after meals. These combined effects contribute directly to lower blood glucose levels and improved A1C, a measure of average blood sugar over two to three months. The significant A1C reductions observed in the Phase 3 trial highlight the effectiveness of retatrutide's GLP-1 component in achieving better glycemic control for people with type 2 diabetes. This is a critical outcome for preventing long-term complications associated with elevated blood sugar.

Beyond GLP-1, retatrutide also activates the GIP receptor. GIP is another incretin hormone that, like GLP-1, enhances glucose-dependent insulin secretion. The combined action of GLP-1 and GIP receptor agonism is believed to be more potent than targeting GLP-1 alone, as seen with some other medications. This dual incretin effect provides a robust mechanism for improving the body's natural insulin response and its ability to process glucose. The third target, the glucagon receptor, adds another layer of metabolic regulation. While glucagon typically raises blood sugar, its modulation by retatrutide in a triple-agonist context is thought to contribute to increased energy expenditure and potentially further support weight loss. The overall effect of simultaneously activating these three pathways is a synergistic action that addresses multiple physiological imbalances present in type 2 diabetes, leading to the significant A1C and weight reductions observed in clinical studies.

The design of retatrutide as a triple agonist represents a sophisticated strategy to tackle the multifaceted nature of type 2 diabetes. Traditional treatments often focus on one or two mechanisms, but the interplay of GLP-1, GIP, and glucagon pathways offers a broader therapeutic impact. The significant weight reductions seen in the Phase 3 trial are particularly important for type 2 diabetes patients, as obesity is a major risk factor and often coexists with the condition. Reducing body weight can improve insulin sensitivity, decrease the burden on the pancreas, and lead to better overall metabolic health. The clinical trial data, specifically from the first Phase 3 study, provides strong evidence that this triple-hormone approach is highly effective in both lowering blood sugar and reducing weight for individuals living with type 2 diabetes. This positions retatrutide as a potentially powerful new tool in the fight against this chronic disease, offering a more comprehensive solution than many currently available treatments.

What Are the Weight Loss Results for Retatrutide?

Retatrutide has shown significant promise for weight loss, not only in individuals with type 2 diabetes but also in those with obesity or who are overweight. In its initial Phase 3 trial, which focused on type 2 diabetes, retatrutide led to significant weight reductions alongside improvements in A1C levels Lilly's Retatrutide Phase 3 Diabetes Trial. This dual benefit is particularly impactful because weight management is a critical component of diabetes care and overall metabolic health. The ability of retatrutide to induce substantial weight loss suggests its potential as a leading treatment for obesity as a standalone condition.

To further explore its efficacy specifically for weight management, Eli Lilly is conducting dedicated studies. One such active study is NCT05929066, which is specifically designed for participants who have obesity or are overweight Retatrutide Obesity/Overweight Study Details. This trial is currently recruiting, indicating that researchers are gathering more data to understand the full scope of retatrutide's impact on body weight in a broader population. The triple-agonist mechanism of retatrutide—targeting GLP-1, GIP, and glucagon receptors—is thought to contribute to its powerful weight-reducing effects. These hormones play key roles in regulating appetite, satiety, and energy expenditure. By activating these pathways, retatrutide helps to reduce food intake, increase feelings of fullness, and potentially boost metabolism, all of which contribute to weight loss.

The significant weight loss observed in the diabetes trial is a strong indicator of what might be expected in the dedicated obesity studies. Typically, medications that show robust weight loss in diabetic populations often exhibit even greater or comparable effects in non-diabetic obese individuals, given that the primary mechanism is often related to appetite suppression and metabolic improvements. The ongoing study NCT05929066 will provide crucial information on the magnitude and consistency of weight loss with retatrutide in a population where obesity is the primary focus. Researchers will be looking at various doses and durations of treatment to optimize the weight loss outcomes while maintaining an acceptable safety profile. The potential for a triple-agonist to induce substantial weight loss is a major area of interest in the medical community, as effective and sustainable weight loss options are greatly needed.

The development of retatrutide for weight loss aligns with a growing understanding that obesity is a complex chronic disease requiring effective pharmacological interventions. The significant reductions in weight seen with retatrutide could offer a new paradigm for treatment, potentially surpassing the weight loss achieved with existing dual agonists or single GLP-1 receptor agonists. The ongoing clinical trials will provide detailed data on the average percentage of body weight lost, the proportion of participants achieving specific weight loss thresholds (e.g., 5%, 10%, 15% body weight reduction), and the long-term sustainability of these results. We anticipate that the results from studies like NCT05929066 will further solidify retatrutide's position as a potent agent for weight management, offering a comprehensive solution for individuals struggling with obesity and its related health complications. The scientific community and patients alike are eagerly awaiting the full data from these critical trials.

How Does Retatrutide Compare to Other GLP-1 Medications?

Retatrutide stands apart from many existing GLP-1 medications due to its unique triple-agonist mechanism, which targets GLP-1, GIP, and glucagon receptors simultaneously. Most GLP-1 medications, like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), primarily activate the GLP-1 receptor, or in the case of tirzepatide (Mounjaro, Zepbound), target both GLP-1 and GIP receptors. By adding glucagon receptor agonism to the mix, retatrutide aims to achieve more comprehensive metabolic effects, potentially leading to greater reductions in A1C and body weight as observed in its first Phase 3 trial for type 2 diabetes Lilly's Retatrutide Phase 3 Diabetes Trial. This multi-pathway approach represents an advancement over current dual or single-agonist therapies.

Eli Lilly, the developer of retatrutide, also has other significant medications in its pipeline, including orforglipron. Orforglipron is an oral GLP-1 medication, which is a major difference from injectable GLP-1s and even retatrutide, which is also an injectable. Orforglipron has demonstrated statistically significant efficacy results in its own Phase 3 trials and a safety profile consistent with injectable GLP-1 medicines Lilly's Oral GLP-1 Orforglipron Efficacy. This oral administration offers a convenience factor that could improve adherence for many patients, a trade-off we examine in our orforglipron evidence review. In terms of weight loss, orforglipron has delivered impressive results, with participants losing up to an average of 27.3 lbs in one pivotal Phase 3 trial in adults with obesity Lilly's Orforglipron Weight Loss Results.

Furthermore, orforglipron has shown unique capabilities in weight maintenance. In the ATTAIN-MAINTAIN trial, participants who switched to orforglipron from injectable incretins like Wegovy or Zepbound were able to maintain their weight loss effectively. Specifically, they maintained all but 0.9 kg of their previously achieved weight loss on average when compared to placebo at 52 weeks Lilly's Orforglipron Weight Maintenance. This demonstrates orforglipron's potential not just for initial weight reduction but also for sustaining those results, which is a significant challenge in obesity management. Orforglipron achieved its primary and all key secondary endpoints for weight maintenance versus placebo at 52 weeks following weight loss on Wegovy or Zepbound Lilly's Orforglipron Weight Maintenance.

When comparing retatrutide and orforglipron, it's important to note their distinct mechanisms and administration routes. Retatrutide, as a triple agonist, is designed for maximum metabolic impact through multiple receptor pathways, offering a potentially powerful injectable solution. Orforglipron, while an oral GLP-1 agonist, provides the convenience of a pill and has shown excellent results in both weight loss and maintenance. The choice between these medications, once approved, would likely depend on individual patient needs, preferences for administration (oral vs. injectable), and the specific metabolic goals. Both drugs represent Eli Lilly's commitment to advancing treatment options for diabetes and obesity, offering different yet highly effective approaches to these widespread health challenges. The ongoing research will continue to clarify their precise comparative benefits and optimal patient populations.

What Are the Current Clinical Trials for Retatrutide?

Eli Lilly is actively conducting multiple clinical trials for retatrutide, also known by its investigational code LY3437943, to thoroughly evaluate its efficacy and safety. These trials are crucial steps in the drug development process, gathering the necessary data for potential regulatory approval. One of the most significant developments is that retatrutide has already demonstrated significant reductions in A1C and weight in its first Phase 3 trial specifically for the treatment of type 2 diabetes Lilly's Retatrutide Phase 3 Diabetes Trial. This initial success in a late-stage trial is a strong indicator of the drug's potential.

Beyond type 2 diabetes, a major focus of current research is on retatrutide's role in weight management for individuals without diabetes. One key ongoing study is NCT05929066, which is titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" Retatrutide Obesity/Overweight Study Details. This particular trial is actively recruiting participants, which means Eli Lilly and its partners are seeking eligible individuals to join the study. The purpose of this study is to specifically assess how effective retatrutide is at helping people lose weight and maintain that weight loss. It also aims to understand the safety profile of the drug in this population.

Clinical trials like NCT05929066 typically involve different arms, where groups of participants receive varying doses of the investigational drug, a placebo, or sometimes an active comparator. These studies are designed to be rigorous, often randomized and double-blinded, to minimize bias and ensure the reliability of the results. Participants in these trials are carefully monitored for changes in body weight, body composition, and various metabolic markers. They also undergo regular assessments for any adverse events or side effects to build a comprehensive safety picture of the drug. The data collected from these trials will be critical in determining the optimal dosing, long-term effectiveness, and overall risk-benefit profile of retatrutide for obesity and overweight.

Eli Lilly's broader clinical trial program for retatrutide is extensive, reflecting the drug's potential across a spectrum of metabolic conditions. These programs often include multiple Phase 3 trials, each designed to answer specific questions about the drug's performance in different patient groups or against different endpoints. For instance, while one trial might focus on A1C and weight in diabetes, another, like NCT05929066, concentrates solely on weight loss in a non-diabetic obese population. The company's commitment to robust clinical research is evident in the detailed information available on platforms like ClinicalTrials.gov and their own Lilly Clinical Trials website. These resources provide transparency into the ongoing studies, including eligibility criteria, study locations, and contact information for interested participants. The ultimate goal of these current clinical trials is to gather sufficient evidence to support retatrutide's potential as a new therapeutic option for millions of people worldwide living with type 2 diabetes and obesity.

Is Retatrutide Safe?

Assessing the safety of any new medication like retatrutide is a primary objective throughout its clinical development process. Since retatrutide is an investigational drug, comprehensive information on its specific safety profile is still being gathered and analyzed within the ongoing clinical trials. During these trials, participants are closely monitored for any adverse events, which are unfavorable changes in health that occur during the study, regardless of whether they are caused by the intervention Study Details | NCT05929066. This meticulous data collection is crucial for building a complete picture of the drug's safety and tolerability.

While specific safety data for retatrutide is still emerging from its trials, we can look at other medications in Eli Lilly's pipeline for contextual understanding. For instance, Lilly's oral GLP-1 medication, orforglipron, which has also completed Phase 3 trials, demonstrated a safety profile consistent with injectable GLP-1 medicines Lilly's Oral GLP-1 Orforglipron Efficacy. This consistency is a positive sign, suggesting that the class of incretin-based therapies generally share similar safety characteristics. Common side effects associated with GLP-1 receptor agonists often include gastrointestinal issues such as nausea, vomiting, diarrhea, or constipation. These side effects are typically mild to moderate and tend to decrease over time as the body adjusts to the medication.

The extensive nature of Phase 3 clinical trials ensures that potential side effects, both common and rare, are identified and thoroughly documented across a large and diverse patient population. The trial protocols are designed to detect any significant safety concerns, and regulatory bodies will carefully review all safety data before considering approval. For retatrutide, researchers are monitoring its effects on various body systems, including cardiovascular, renal, and gastrointestinal functions. The triple-agonist mechanism, while potentially offering enhanced efficacy, also means that the interaction of targeting GLP-1, GIP, and glucagon receptors must be carefully evaluated for any unexpected safety implications.

The goal of these ongoing safety assessments is to ensure that the benefits of retatrutide in terms of A1C reduction and weight loss outweigh any potential risks. Informed consent processes in clinical trials ensure that participants are fully aware of known and potential risks before enrolling. As the trials for retatrutide progress and more data becomes available, detailed safety information will be published. Until then, it's important to recognize that, like all investigational drugs, retatrutide's full safety profile is still under evaluation. However, the experience with other GLP-1 related medications, including Eli Lilly's orforglipron, provides a general framework for the types of safety considerations typically associated with this class of drugs. Patients interested in such therapies should always consult with a qualified healthcare provider for personalized medical advice.

Frequently Asked Questions

What is Retatrutide?

Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly. It is known as a triple agonist, meaning it activates three different hormone receptors: GLP-1, GIP, and glucagon. This unique mechanism is designed to provide comprehensive benefits for managing blood sugar and body weight. In its first Phase 3 trial for type 2 diabetes, retatrutide showed significant reductions in A1C and weight Lilly's Retatrutide Phase 3 Diabetes Trial.

How does Retatrutide help with weight loss?

Retatrutide helps with weight loss by acting on GLP-1, GIP, and glucagon receptors, which collectively influence appetite, satiety, and energy metabolism. By engaging these pathways, it aims to reduce food intake, increase feelings of fullness, and potentially boost energy expenditure. Its initial Phase 3 trial for type 2 diabetes demonstrated significant weight reductions, and a dedicated study (NCT05929066) is actively researching its effects in participants with obesity or who are overweight Retatrutide Obesity/Overweight Study Details.

Is Retatrutide approved for use yet?

No, retatrutide is an investigational drug and is not yet approved for use by regulatory bodies like the FDA. It is currently undergoing rigorous Phase 3 clinical trials to evaluate its efficacy and safety. The results from these trials will be submitted for review before any potential approval for commercial use.

What are the main differences between Retatrutide and Orforglipron?

The main differences lie in their mechanism and administration. Retatrutide is an injectable triple agonist targeting GLP-1, GIP, and glucagon receptors. Orforglipron, also from Eli Lilly, is an oral GLP-1 receptor agonist. Orforglipron delivered weight loss of up to an average of 27.3 lbs in one pivotal Phase 3 trial in adults with obesity and helped people maintain weight loss after switching from injectable incretins Lilly's Orforglipron Weight Loss Results.

Where can I find more information about Eli Lilly's clinical trials for Retatrutide?

You can find more information about Eli Lilly's clinical trials for retatrutide on official clinical trial registries. For example, you can visit ClinicalTrials.gov and search for the study identifier NCT05929066, which details a study of retatrutide in participants with obesity or overweight Retatrutide Obesity/Overweight Study Details. Eli Lilly's own clinical trials website also provides information on their ongoing research programs.

Retatrutide: Eli Lilly's Triple Agonist Full Review

Quick Answer

What is Retatrutide?

How Does Retatrutide Work for Type 2 Diabetes?

What Are the Weight Loss Results for Retatrutide?

How Does Retatrutide Compare to Other GLP-1 Medications?

What Are the Current Clinical Trials for Retatrutide?

Is Retatrutide Safe?

Frequently Asked Questions

What is Retatrutide?

How does Retatrutide help with weight loss?

Is Retatrutide approved for use yet?

What are the main differences between Retatrutide and Orforglipron?

Where can I find more information about Eli Lilly's clinical trials for Retatrutide?

Sources

Related Reading

Get our answers in your Google results.

Which GLP-1 medication might work for you?

Related

Sam's Club Wegovy Partnership: Is It Worth It?

Activ-2 Results: Retatrutide Phase 3 Preview

Tirzepatide Long-Term Safety Data Reviewed

Stay in the loop